Aptevo Therapeutics Inc

Aptevo Therapeutics Inc. (www.aptevotherapeutics.com) is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The Company has two modular protein platforms of technology: ADAPTIR and ADAPTIR-FLEX. It is designed to generate monospecific, bispecific and multi-specific antibody candidates that are capable for the human immune system against cancer cells. The Company's lead product candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using the ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using the ADAPTIR-FLEX modular protein technology platform. APVO436 is a recombinant, bispecific T-cell engaging antibody candidate that is designed to target CD123, CD3 and redirect T-cell cytotoxicity to the tumor.

• Aptevo Therapeutics Inc